Transaction overview
JB Capital acquired a 50% stake in Grupo Sesderma, a Spanish company that owns and operates dermatological brands such as Sesderma, Mediderma, and Dermopartners. The deal closed on July 23, 2026, with an investment of €40 million to support the company's expansion plans in the dermocosmetics market.
Deal structure and financing
The transaction includes a refinancing component through a flexible capital solution provided by Kartesia, a pan-European asset manager. JB Capital injected €40 million in new equity while Kartesia participated with long-term debt to refinance Grupo Sesderma's financial liabilities. The exact split between equity and debt is not disclosed but the agreement provides for an optimal capital structure that supports the company’s growth plans. No specific lock-up terms or IPO optionality were mentioned, although JB Capital will take operational control of the group while Dr. Gabriel Serrano retains leadership over scientific and R&D activities.
Strategic context
JB Capital's acquisition is driven by its long-term commitment to accelerate Grupo Sesderma's expansion in the dermocosmetics market, which is projected to grow at a CAGR of more than 6% through 2030. The deal enables JB Capital to professionalize and enhance the company’s operational management while allowing Dr. Gabriel Serrano to focus on scientific innovation and R&D efforts. This strategic alignment aims to leverage Grupo Sesderma's established brand strength in Spain and its international presence across more than 90 countries.
Regulatory path
No specific regulatory review process was disclosed for this transaction, though it likely involved antitrust scrutiny given the deal size and sectors involved. The jurisdictions most relevant would be the European Union due to Grupo Sesderma’s operations across multiple EU member states, as well as Spain where both parties are headquartered. No details on any required remedies or HSR filings were provided, but standard regulatory timelines for approval in such cases typically range from several weeks to a few months depending on complexity and jurisdictional requirements.